We are live on ! Find out more
Ken Griffin

Ken Griffin Citadel Advisors

AUM $618B
1-Year Est. Return 30.34%
 

Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.

This Fund
S&P 500
This Quarter Est. Return
+6.7%
1 Year Est. Return
+30.34%
3 Year Est. Return
+94.87%
5 Year Est. Return
+105.94%
10 Year Est. Return
+434.06%
AUM
$164B
AUM Growth
+$34B
Cap. Flow
+$21.1B
Cap. Flow %
12.82%
Top 10 Hldgs %
19.02%
Holding
8,908
New
1,440
Increased
3,569
Reduced
2,696
Closed
988

Sector Composition

Rank Sector Weight
1 Technology 6.22%
2 Financials 6.16%
3 Industrials 5.09%
4 Consumer Discretionary 4.89%
5 Healthcare 4.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FTEK icon
7601
Fuel Tech
FTEK
$45.9M
$30K ﹤0.01%
27,026
+2,820
+12% +$2.85K
VXRT
7602
DELISTED
Vaxart
VXRT
$30K ﹤0.01%
4,775
+2,616
+121% +$18.3K
INFI
7603
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$30K ﹤0.01%
+15,000
New +$31.1K
SPI
7604
DELISTED
SPI Energy Co., Ltd. Ordinary Shares
SPI
$30K ﹤0.01%
+4,723
New +$48.7K
CVEO icon
7605
CALL
Civeo
CVEO
$345M
$29K ﹤0.01%
+875
New +$24.1K
INSG icon
7606
Inseego
INSG
$77.7M
$29K ﹤0.01%
+1,815
New +$28.2K
UAMY icon
7607
United States Antimony
UAMY
$799M
$29K ﹤0.01%
+89,691
New +$23.6K
INFI
7608
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$29K ﹤0.01%
14,171
+3,581
+34% +$7.43K
GCVRZ
7609
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$29K ﹤0.01%
76,245
-11,166
-13% -$4.24K
ACGN
7610
PUT
DELISTED
Aceragen Inc
ACGN
$28K ﹤0.01%
+99
New +$28.3K
ATRS
7611
PUT
DELISTED
Antares Pharma, Inc.
ATRS
$28K ﹤0.01%
14,000
-6,500
-32% -$14.1K
GSS
7612
PUT
DELISTED
Golden Star Resources Ltd.
GSS
$28K ﹤0.01%
6,220
+1,860
+43% +$7.52K
GMO
7613
DELISTED
General Moly, Inc.
GMO
$28K ﹤0.01%
83,720
+54,676
+188% +$17.4K
PTX
7614
CALL
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$28K ﹤0.01%
11,500
-2,600
-18% -$7.19K
EVK
7615
DELISTED
Ever-Glory International Group, Inc.
EVK
$28K ﹤0.01%
+12,122
New +$28.3K
OCGN icon
7616
Ocugen
OCGN
$458M
$27K ﹤0.01%
+221
New +$27K
QUIK icon
7617
CALL
QuickLogic
QUIK
$230M
$27K ﹤0.01%
1,093
-643
-37% -$14.5K
STRR
7618
DELISTED
Star Equity Holdings
STRR
$27K ﹤0.01%
+211
New +$25.4K
TMQ
7619
Trilogy Metals
TMQ
$653M
$27K ﹤0.01%
25,003
+10,068
+67% +$9.66K
ATRS
7620
DELISTED
Antares Pharma, Inc.
ATRS
$27K ﹤0.01%
13,498
-101,350
-88% -$221K
TISA
7621
DELISTED
TOP Image Systems Ltd
TISA
$27K ﹤0.01%
23,466
+5,663
+32% +$6.88K
EVOK
7622
DELISTED
Evoke Pharma
EVOK
$26K ﹤0.01%
+81
New +$33.6K
GERN icon
7623
CALL
Geron
GERN
$982M
$26K ﹤0.01%
+14,600
New +$29.5K
MGNI icon
7624
CALL
Magnite
MGNI
$3.53B
$26K ﹤0.01%
+13,800
New +$34.5K
NEGG icon
7625
Newegg Commerce
NEGG
$415M
$26K ﹤0.01%
92
-3
-3% -$738

Similar funds

Ken Griffin's Q4 2017 Portfolio in Review

As of Q4 2017, Ken Griffin held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Ken Griffin deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.

By sector, the portfolio is most concentrated in Technology at 6.2% of assets, down from 7.2% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.

  • Ken Griffin's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
  • Ken Griffin added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
  • Ken Griffin's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
  • Ken Griffin fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
  • Ken Griffin's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
  • Ken Griffin opened 1,440 new positions and closed 988 in Q4 2017.
  • Ken Griffin's portfolio value rose 26% quarter-over-quarter to $164B.

Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.